These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1728845)

  • 1. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin).
    Hauptman JB; Jeunet FS; Hartmann D
    Am J Clin Nutr; 1992 Jan; 55(1 Suppl):309S-313S. PubMed ID: 1728845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on the antiobesity activity of tetrahydrolipstatin, a potent and selective inhibitor of pancreatic lipase.
    Hogan S; Fleury A; Hadvary P; Lengsfeld H; Meier MK; Triscari J; Sullivan AC
    Int J Obes; 1987; 11 Suppl 3():35-42. PubMed ID: 3440690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity.
    Weibel EK; Hadvary P; Hochuli E; Kupfer E; Lengsfeld H
    J Antibiot (Tokyo); 1987 Aug; 40(8):1081-5. PubMed ID: 3680018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tetrahydrolipstatin, a lipase inhibitor, on absorption of fat from the intestine of the rat.
    Fernandez E; Borgström B
    Biochim Biophys Acta; 1989 Feb; 1001(3):249-55. PubMed ID: 2917150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers.
    Bryson A; de la Motte S; Dunk C
    Br J Clin Pharmacol; 2009 Mar; 67(3):309-15. PubMed ID: 19220279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mode of action of orlistat.
    Guerciolini R
    Int J Obes Relat Metab Disord; 1997 Jun; 21 Suppl 3():S12-23. PubMed ID: 9225172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the inhibition of dietary fat absorption by full versus divided doses of orlistat.
    Hussain Y; Güzelhan C; Odink J; van der Beek EJ; Hartmann D
    J Clin Pharmacol; 1994 Nov; 34(11):1121-5. PubMed ID: 7876405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the lipase inhibitor orlistat and of dietary lipid on the absorption of radiolabelled triolein, tri-gamma-linolenin and tripalmitin in mice.
    Isler D; Moeglen C; Gains N; Meier MK
    Br J Nutr; 1995 Jun; 73(6):851-62. PubMed ID: 7632666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake.
    Hartmann D; Hussain Y; Güzelhan C; Odink J
    Br J Clin Pharmacol; 1993 Sep; 36(3):266-70. PubMed ID: 9114915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers.
    Zhi J; Melia AT; Guerciolini R; Chung J; Kinberg J; Hauptman JB; Patel IH
    Clin Pharmacol Ther; 1994 Jul; 56(1):82-5. PubMed ID: 8033498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin.
    Borgström B
    Biochim Biophys Acta; 1988 Oct; 962(3):308-16. PubMed ID: 3167082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers.
    Melia AT; Zhi J; Zelasko R; Hartmann D; Güzelhan C; Guerciolini R; Odink J
    Eur J Clin Pharmacol; 1998; 54(9-10):773-7. PubMed ID: 9923583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ebelactone B, a lipase inhibitor, on intestinal fat absorption in the rat.
    Nonaka Y; Ohtaki H; Ohtsuka E; Kocha T; Fukuda T; Takeuchi T; Aoyagi T
    J Enzyme Inhib; 1996; 10(1):57-63. PubMed ID: 8835930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of lipases from Chromobacterium viscosum and Rhizopus oryzae by tetrahydrolipstatin.
    Potthoff AP; Haalck L; Spener F
    Biochim Biophys Acta; 1998 Jan; 1389(2):123-31. PubMed ID: 9461253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of dietary composition on the inhibition of fat absorption by orlistat.
    Güzelhan C; Odink J; Niestijl Jansen-Zuidema JJ; Hartmann D
    J Int Med Res; 1994; 22(5):255-65. PubMed ID: 7867870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacy-clinics medication of the month. Orlistate (xenical)].
    Scheen AJ; Ernest P; Letiexhe MR
    Rev Med Liege; 1999 Mar; 54(3):192-6. PubMed ID: 10321111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-obesity effects in rodents of dietary teasaponin, a lipase inhibitor.
    Han LK; Kimura Y; Kawashima M; Takaku T; Taniyama T; Hayashi T; Zheng YN; Okuda H
    Int J Obes Relat Metab Disord; 2001 Oct; 25(10):1459-64. PubMed ID: 11673766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orlistat inhibits dietary cholesterol absorption.
    Mittendorfer B; Ostlund RE; Patterson BW; Klein S
    Obes Res; 2001 Oct; 9(10):599-604. PubMed ID: 11595776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of hypolipidemic effect of crocin in rats: crocin inhibits pancreatic lipase.
    Sheng L; Qian Z; Zheng S; Xi L
    Eur J Pharmacol; 2006 Aug; 543(1-3):116-22. PubMed ID: 16828739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.